For US Healthcare Professionals Only
Publications
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.
*Includes seizure clusters and acute or prolonged seizures
197 result(s)
phase
3
BIMZELX® (bimekizumab-bkzx)
Plaque Psoriasis
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results form the open-label extension of the randomized BE RADIANT phase 3b trial.
phase
3
ZILBRYSQ® (zilucoplan)
Generalized Myasthenia Gravis
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
CIMZIA® (certolizumab pegol)
Non-radiographic Axial Spondyloarthritis
Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons
phase
3
BIMZELX® (bimekizumab-bkzx)
Plaque Psoriasis
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab, or secukinumab: Results from phase III/IIIb trials.
phase
2
BIMZELX® (bimekizumab-bkzx)
Psoriatic Arthritis
Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE
phase
3
BIMZELX® (bimekizumab-bkzx)
Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
phase
3
BIMZELX® (bimekizumab-bkzx)
Psoriatic Arthritis
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
phase
3
BIMZELX® (bimekizumab-bkzx)
Psoriatic Arthritis
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
phase
3
CIMZIA® (certolizumab pegol)
Plaque Psoriasis
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)